Skip to main content
. 2011 Mar 20;14(3):261–265. [Article in Chinese] doi: 10.3779/j.issn.1009-3419.2011.03.22

1.

1

EGFR 21外显子突变(A)、初始TKI缓解期≥6个月(B)及两次TKI间隔期≥3个月(C)对再次应用TKI的影响

Influence of Exon 21 mutation (A), progression free survival not less than 6 months (B), the period of time (not less than 3 months) following the termination of the initial TKI treatment (C) to retreatment TKI